Clarithromycin

Clarithromycin is a member of the macrolide class of antibiotics. Chemically it is erythromycin modified at one position, a change that makes it more stable in stomach acid and better absorbed, allowing twice-daily dosing. After absorption it is converted in the liver to an active metabolite, 14-hydroxyclarithromycin, which adds to its antibacterial effect, and the drug distributes widely, reaching higher concentrations in tissues than in blood ^[1].

The antibiotic was invented by the Japanese company Taisho around 1980, and Abbott Laboratories brought it to market as Biaxin, gaining United States approval in 1991; it is now a widely available generic. It is used for community-acquired respiratory infections such as pneumonia and bronchitis, for skin and soft-tissue infections, as part of combination regimens to eradicate Helicobacter pylori in peptic ulcer disease, and against mycobacterial infections including Mycobacterium avium complex.

Clarithromycin is defined clinically as much by its interactions and safety cautions as by its antibacterial activity. It is a strong inhibitor of the liver enzyme CYP3A4, so it can raise the blood levels of many co-prescribed drugs to harmful concentrations. A large population-based study found that older adults taking a calcium channel blocker who were given clarithromycin, rather than the non-interacting macrolide azithromycin, had a higher risk of hospitalization for acute kidney injury, low blood pressure, and death ^[3]. The drug can also prolong the heart's QT interval; in the CLARICOR trial, a short course of clarithromycin in patients with stable coronary heart disease was associated with an excess of sudden cardiac deaths, particularly in those not taking statins ^[2].

Clarithromycin is a prescription-only medicine and is available as immediate-release and extended-release tablets and as an oral suspension. Because of its interaction profile and cardiac cautions, prescribers weigh it carefully against alternatives in patients with heart disease or complex medication regimens.

Clarithromycin is prescription only. Common side effects include a metallic or altered taste, nausea, diarrhea, and stomach upset. It can prolong the QT interval and rarely trigger dangerous heart rhythms, and it can strain the liver. It is a strong inhibitor of the CYP3A4 enzyme, so it raises levels of many drugs; combining it with certain statins can cause muscle breakdown, with colchicine can cause toxicity, and with warfarin can raise bleeding risk. Long term use in people with coronary artery disease has been linked to higher cardiac mortality. It should be avoided with several QT prolonging drugs and used carefully in liver or kidney impairment.

Clarithromycin is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor, which makes it one of the most interaction-prone antibiotics in use. With simvastatin or lovastatin, both heavily CYP3A4-dependent, exposure can rise several-fold and rhabdomyolysis follows; pravastatin and rosuvastatin are not cleared that way. Colchicine is the deadliest pairing, since clarithromycin blocks both its metabolism and its P-glycoprotein efflux, and fatal colchicine toxicity has been reported in people with renal impairment. Ergot alkaloids can produce ischemia and gangrene by the same route.

Beyond that, clarithromycin raises exposure to midazolam, tacrolimus, calcium channel blockers, warfarin, carbamazepine and digoxin; hypotension and acute kidney injury are a recognized outcome of the calcium channel blocker pairing in older adults.

Clarithromycin also prolongs the QT interval, so other QT-prolonging drugs add to the torsades risk, and the combination with pimozide is contraindicated.

Checking a whole stack? Run it through interactions + stacks.

Clarithromycin was developed by the Japanese company Taisho Pharmaceutical during the late 1970s and 1980s as a semisynthetic improvement on erythromycin, the original macrolide. The chemists added a single methyl group at the 6-position of the erythromycin molecule, a small change that greatly increased acid stability and oral absorption while reducing the gastrointestinal upset that limited its predecessor. It was first approved in Japan in 1990 and reached the United States in 1991, marketed by Abbott Laboratories as Biaxin.

Over the following decades it became a cornerstone of two important regimens, triple therapy for Helicobacter pylori and combination treatment for Mycobacterium avium complex, and it earned a place on the World Health Organization list of essential medicines. Its later reputation was shaped as much by safety scrutiny as by efficacy, notably after the CLARICOR trial reported higher long-term cardiovascular mortality following a short course in patients with stable coronary disease.

Clarithromycin is regarded as a valuable and versatile macrolide, generally better tolerated and more reliably absorbed than the erythromycin from which it was derived. It is respected as a backbone of Helicobacter pylori eradication and mycobacterial therapy, and it remains a familiar choice for respiratory and soft-tissue infections. In candid terms, its standing is tempered by two well-known concerns; as a strong inhibitor of the CYP3A4 enzyme it can dangerously raise the levels of many co-administered drugs, and it can prolong the cardiac QT interval, a property linked to the excess cardiovascular deaths seen in the CLARICOR trial. Rising macrolide resistance has also complicated its use in Helicobacter pylori regimens. Weighed together, it is viewed as an effective agent that rewards careful attention to interactions and cardiac risk.